AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive cover art

AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive

AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive

Listen for free

View show details

Summary

 🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data. In Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies. Because patients do not walk into clinic asking if their EASI score improved by 70%. They ask: “Will I sleep?”“Will the itch stop?”“Can I focus at work or school?”“Can I stop thinking about my eczema every single day?” Our conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis. We also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders? Think of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care. Learning Objectives: By the end of this episode, listeners will be able to: Describe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis.Discuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone.Interpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies.Identify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice.Apply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care. Skin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting. Part 2 is already warming up in the bullpen. REFERENCES: Long-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻...
adbl_web_anon_alc_button_suppression_c
No reviews yet